Use of a neurofilament peptide for the treatment of glioma
US9446092B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 14, 2010 |
| Grant date | Sep 20, 2016 |
| Priority date | — |
| Expiry date | Dec 14, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57407
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.